Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for synthesis of favipiravir

A synthetic method, the technology of favipiravir, applied in the field of drug synthesis, can solve the problems of difficult industrial production requirements, low yield, low efficiency, etc., and achieve the effect of simple operation, high yield, and simplified preparation process

Inactive Publication Date: 2017-06-20
CENT SOUTH UNIV
View PDF8 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In order to solve the problem of key impurities, the existing technology often adopts chromatographic purification methods. This type of treatment method has a series of defects such as large solvent consumption, low efficiency, and low yield, which is difficult to meet the needs of industrial production; The yield is high, and the synthetic method of target product quality controllability just seems particularly important; The inventor has developed a kind of synthetic method of favipiravir without chromatographic purification, product quality controllable, and high yield through a large amount of research, as follows Shown:

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for synthesis of favipiravir
  • Method for synthesis of favipiravir
  • Method for synthesis of favipiravir

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0138] The first step: preparation of 3-amino-2-ester pyrazine (2)

[0139]

[0140] Add methanol (50ml) to compound 1 (5g, leq), add concentrated sulfuric acid (4eq) under an ice-water bath, stir at room temperature, TLC shows that the reaction is complete, concentrate, adjust the pH to 8 with saturated sodium carbonate, filter with suction, and dry at 50°C for 2h. Obtained 2 as a brown solid (4.18 g, 76%).

[0141] The second step: preparation of methyl 3-amino-6-bromopyrazine-2-carboxylate (3)

[0142]

[0143]Add acetonitrile (276ml) to compound 2 (27.6g, leq), stir at room temperature, add NBS (25.1g, 1.01eq) in batches, stir overnight at room temperature, TLC shows that after the reaction is complete (20-30h), add water (300ml), use Na 2 CO 3 The solution was adjusted to pH=7, extracted with ethyl acetate (3×50ml), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain 3...

Embodiment 2

[0163] Compared with Example 1, the difference is only in:

[0164] The fifth step: preparation of 3,6-dichloropyrazine-2-carbonitrile (6)

[0165] Compound 5 (2g, 1eq) was dissolved in chlorobenzene (10ml), POCl was slowly added dropwise 3 (5.6g, 4eq), heated to 70°C to form a homogeneous solution, lowered to room temperature, added DIEA (3.57g, 3eq) dropwise, stirred for 1h at 60°C, 1h at 80°C, and 4h at 100°C. Afterwards, it was poured into ice water (110ml) and stirred vigorously to react for 2h, suction filtered, and 20 times of petroleum ether was used for the filter cake (the weight ratio of the obtained crude product to petroleum ether was 1:10-30) to obtain a brown solid 6 in a yield of 60 %.

[0166] The remaining steps are the same as in Example 1.

Embodiment 3

[0168] Compared with embodiment 1, the difference only lies in:

[0169] The crude product of 3-amino-6-bromopyrazine-2-carboxylic acid methyl ester obtained in the second step was added 30 times of dichloromethane (the weight ratio of the obtained crude product to dichloromethane was 1:25~50) and refluxed for 0.5h Afterwards, suction filtration, the dichloromethane was evaporated from the mother liquor, and then recrystallized with 20 times of methanol (the weight ratio of rotary steamed product and methanol was 1:5-30) to obtain light yellow solid 3 with a yield of 76%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for synthesis of favipiravir. The method comprises an esterification reaction of 3-aminopyrazine-2-carboxylic acid and an alcohol, a bromination reaction, a diazotization reaction, an ammonolysis reaction, a chlorination-dehydration reaction, a one-pot series connection aromatic ring fluorination reaction, a cyan-hydrolysis reaction, an aromatic ring hydroxyl substitution reaction, and purification treatment so that favipiravir is obtained. The method utilizes 3-amino-2-carboxypyrazine as a raw material to synthesize favipiravir through 8-step reactions and has a total yield of 26%. The key intermediates 3 and 6 in the method are purified by recrystallization so that column chromatography separation in the literature is avoided. The final three reactions are finished by a one-pot method so that the operation is simplified. The synthesis method improves a yield, realizes a low cost and green economy and is conducive to industrial production.

Description

technical field [0001] The invention belongs to the field of drug synthesis, and in particular relates to a new preparation method of Favipiravir. Background technique [0002] Favipiravir (favipiravir), the chemical name is 6-fluoro-3-hydroxypyrazine-2-carboxamide, and the molecular formula is: C 5 h 4 N 3 o 2 F, molecular weight: 157.1, has the following structural formula: [0003] [0004] Favipiravir was researched and developed by Toyama Chemical Co., Ltd., Japan. In 2011, it completed Phase III clinical trials in Japan. It was approved for marketing in 2014. It is mainly used for influenza treatment in clinical practice. It is a wide range of RNA-dependent RNA polymerase inhibitors. Spectrum antiviral drugs. Studies have shown that Favipiravir forms Favipiravir-ribofuranosyl-5-triphosphate (T-705RTP) under the action of intracellular enzymes, which competitively inhibits viral RNA-dependent RNA polymerase, thereby inhibiting the viral genome Replication and t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D241/24
CPCC07D241/24
Inventor 刘丰良李翠钦
Owner CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com